Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.97 +1.0%	$2.75	$0.40 ▼ $5.48	$50.44M	0.27	482,299 shs	77,893 shs
DARE Dare Bioscience	$2.11 +3.9%	$2.60	$1.83 ▼ $9.19	$19.05M	1.11	636,687 shs	218,276 shs
KA Kineta		$0.66	$0.33 ▼ $5.39	$7.04M	0.46	409,478 shs	530,700 shs
VOR Vor Biopharma	$2.02 +21.7%	$1.48	$0.13 ▼ $3.29	$255.81M	2.06	8.09 million shs	27.58 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-0.34%	-2.00%	-25.94%	+101.37%	+328.07%
DARE Dare Bioscience	+3.05%	-15.42%	-19.44%	-29.76%	-42.00%
KA Kineta	0.00%	0.00%	0.00%	0.00%	-5.80%
VOR Vor Biopharma	-16.58%	-23.85%	-33.60%	+870.76%	+102.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	1.1183 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.8	0.0
DARE Dare Bioscience	1.573 of 5 stars	3.3	2.0	0.0	0.0	3.1	0.0	0.0
KA Kineta	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	2.2101 of 5 stars	3.3	0.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	468.72% Upside
KA Kineta	0.00	N/A	N/A	N/A
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	178.64% Upside

Current Analyst Ratings Breakdown

Latest KA, ABVC, VOR, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$508.38K	99.21	N/A	N/A	$0.06 per share	49.50
DARE Dare Bioscience	$25.91K	735.39	N/A	N/A	($0.69) per share	-3.06
KA Kineta	$5.44M	0.00	N/A	N/A	$0.29 per share	0.00
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	N/A	N/A	-8.14%	8/14/2025 (Estimated)
KA Kineta	-$14.10M	-$1.50	N/A	N/A	N/A	N/A	-1,044.95%	-336.46%	N/A
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KA, ABVC, VOR, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	N/A	N/A	N/A	$0.14 million	N/A
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
KA Kineta	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
DARE Dare Bioscience	N/A	0.56	0.56
KA Kineta	0.05	0.14	0.14
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
DARE Dare Bioscience	6.70%
KA Kineta	30.32%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
DARE Dare Bioscience	4.80%
KA Kineta	23.70%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
DARE Dare Bioscience	30	9.03 million	8.60 million	Not Optionable
KA Kineta	40	12.25 million	9.35 million	Not Optionable
VOR Vor Biopharma	140	126.64 million	65.45 million	Not Optionable

KA, ABVC, VOR, and DARE Headlines

Recent News About These Companies

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13 at 1:30 PM | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13 at 1:30 PM | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13 at 12:06 PM | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13 at 8:30 AM | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

July 20, 2025 | msn.com

Vor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing Zuraw

July 18, 2025 | quiverquant.comQ

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | globenewswire.com

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

July 17, 2025 | globenewswire.com

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KA, ABVC, VOR, and DARE Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.97 +0.03 (+1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.90 -0.07 (-2.49%)

As of 07:55 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Dare Bioscience NASDAQ:DARE

$2.11 +0.08 (+3.94%)

Closing price 04:00 PM Eastern

Extended Trading

$2.06 -0.05 (-2.37%)

As of 07:55 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Kineta NASDAQ:KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Vor Biopharma NYSE:VOR

$2.02 +0.36 (+21.69%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 -0.04 (-2.23%)

As of 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time